pembrolizumab + vibostolimab + carboplatin + pemetrexed

This is an investigational **combination therapy** consisting of *pembrolizumab* (a PD-1 immune checkpoint inhibitor), *vibostolimab* (an anti-TIGIT monoclonal antibody), *carboplatin* (a platinum-based chemotherapeutic), and *pemetrexed* (an antimetabolite chemotherapy). Pembrolizumab blocks the programmed cell death protein 1 (PD-1) pathway to promote antitumor immune activity. Vibostolimab inhibits TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domain), aiming to enhance immune activation against cancer cells. Carboplatin induces DNA crosslinking and cell death, while pemetrexed disrupts folate-dependent metabolic processes in tumor cells. This specific combination is under investigation in advanced solid tumors, particularly non-small cell lung cancer (NSCLC), as part of the KEYVIBE-007 and related Merck-sponsored trials, in the first-line treatment of metastatic nonsquamous NSCLC. The combination aims to synergize immunotherapeutic and cytotoxic effects for improved antitumor activity[2][3][5].

Brand names

None (individual drugs: Keytruda for pembrolizumab, Alimta for pemetrexed, Paraplatin for carboplatin, but no unique brand for the quadruple combination)

Other names

None (the exact 4-drug combination has no other commonly used name)